Showing 18,181 - 18,200 results of 43,973 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((mean decrease) OR (nn decrease)) ))', query time: 1.28s Refine Results
  1. 18181

    The intrinsic fluctuations follow a binomial distribution and can maximize their variance away from the threshold of the response curve. by Bruno M.C. Martins (340291)

    Published 2013
    “…<p>(<b>A</b>) Comparison between Eq. (5) (in dark blue) and numerical simulation (red line). …”
  2. 18182
  3. 18183
  4. 18184

    Biosynthesis, characterisation and biocompatibility of a unique and elastomeric medium chain-length polyhydroxyalkanoates for kidney glomerular tissue engineering by Syed Mohammad Daniel Syed Mohamed (19836277)

    Published 2025
    “…These polymers are not only highly biocompatible in nature but also sustainable, produced using renewable substrates, and hence considered future biomaterials. This study explores a medium chain-length PHA (mcl-PHA) produced by <em>Pseudomonas mendocina </em>CH50 by batch fermentation, fed with glucose as the sole carbon source. …”
  5. 18185

    Table_1_Association between dietary habits and incident thyroid cancer: A prospective cohort study.DOCX by Linh Thi Dieu Nguyen (14619104)

    Published 2023
    “…However, this association was limited to individuals aged ≥ 50 years (aHR, 0.49; 95% CI, 0.31–0.79), women (aHR, 0.61; 95% CI, 0.41–0.90), and non-smokers (aHR, 0.62; 95% CI, 0.41–0.92).…”
  6. 18186

    Image_1_Triglyceride–glucose index change and chronic kidney disease progression in a Chinese hypertensive population.pdf by Chao Yu (562804)

    Published 2024
    “…The study’s outcome variable was the progression of CKD, defined as follows: for subjects with an estimated glomerular filtration rate (eGFR) ≥60 mL/min, a ≥30% decrease in eGFR with a final follow-up value <60 mL/min; for those with an eGFR <60 mL/min, a50% decrease in eGFR; or terminal renal failure requiring dialysis.…”
  7. 18187
  8. 18188
  9. 18189
  10. 18190
  11. 18191
  12. 18192

    Data_Sheet_1_Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.pdf by Paige Baldwin (6688517)

    Published 2019
    “…However, its potency lends itself to side effects associated more closely with traditional chemotherapeutics than other clinically approved PARP inhbitors. We sought to formulate Talazoparib in a nanoparticle delivery system, which allows the drug to be administered intraperitoneally. …”
  13. 18193

    DataSheet_1_Molecular mechanisms regulating natural menopause in the female ovary: a study based on transcriptomic data.xlsx by Quan Liu (486219)

    Published 2023
    “…Increased contents of terminally differentiated HMGB1+ Granulosa and GSTA1+ Granulosa were observed in the ovaries of individuals aged 50-69. Signaling pathway activity analysis indicated a gradual decrease in TGFb and MAPK pathway activity with menopause progression, while p53 pathway activity increased. …”
  14. 18194
  15. 18195
  16. 18196
  17. 18197
  18. 18198
  19. 18199
  20. 18200